Period in Medical Technology

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... 30, 2009, a significant improvement over the same period in 2008. Isis also reported a pro forma net ... net operating income of $4.6 million for the same period in 2008. Maintaining its strong cash position, ... continuing operations of $463,000 for the same period in 2008. For the six months ended June 30, 2009 ...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

... programs. Revenue for the three month period ended June 30, 2009 was $13.0 million compared to ... Cash and cash equivalents at beginning of period 155,584 76,293 ... ------ Cash and cash equivalents at end of period $114,992 $31,829 ...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

... patient achieved a CRu during the follow-up period of patients that received chemotherapy on the ... chemotherapy with p=0.001. The follow-up period of this study is ongoing. CTI expects an ... complete remission after the initial assessment period with pixantrone compared to other agents. These ...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

... daily versus placebo over a two-year treatment period in obese patients (Body Mass Index, or BMI, 30 to ... daily versus placebo over a one-year treatment period in obese patients with or without co-morbid ... daily versus placebo over a one-year treatment period in obese and overweight patients with type 2 ...

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

... as those who refilled their prescription within a period of up to twice the duration of the prescription ... on their prescribed therapy over an extended period of time. The study evaluated a total of 44,191 ... who refilled their prescription after the grace period of twice the duration of their prescription had ...

Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis

... than in the placebo group. Over the two-year period of the study, 80% of the patients treated with ... endpoint) relative to placebo over the two-year period of the study (low-dose regimen: hazard ... with clinical outcomes. Over the two year period of the study, both dose regimens of Cladribine ...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results

... million from $8.9 million for the corresponding period in 2008. The decrease for the three months ended ... million from $27.8 million for the corresponding period in 2008. The decrease was primarily attributable ... million from $5.5 million for the corresponding period in 2008. The decrease was primarily attributable ...

New Weight Loss Hope for People with Diabetes

... 18 pounds during the initial 12 week assessment period and lowered their A1C test, by 0.9. By ... and education program over the initial 12 week period lost on average one pound, while their average ... by 0.03. During a subsequent 12 week period in which all of the study participants followed ...

DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program

... maintenance period, followed by a 7-day follow-up period to ensure that an adequate pain control regimen ... to stable pain control and into the maintenance period (see above), the conversion ratios from oral ... study, the mean pain score during the maintenance period of 3.88 (on a numerical ratings scale for pain ...

Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)

... placebo was maintained over the 28-day treatment period (p <0.01). More importantly, in the 25 mg and ... were sustained over the entire 28-day treatment period without opiate withdrawal or reversal of ... was a change in SBMs from a two-week baseline period during which the patient had to demonstrate ...

Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder

... compared the rate of stroke in the eight-year period after TCD screening began at the Children's Hospital of Philadelphia with that of the eight-year period prior to the implementation of TCD screening. The ... of patients who received the therapy over a long period of time. The medical records of 330 patients with ...

Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

... HCl 3.75 g/day during the double-blind period were maintained through the 18-week open-label ... by an eight-week, double-blind period in which patients were randomized to either ... 3.75 g/day (n=64). The eight-week, double-blind period was followed by an 18-week open-label treatment ...

SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results

... 30, 2008, compared to $207,474 for the same period in 2007. This increase is primarily due to higher ... to a net loss of ($3.1) million for the same period in 2007. Net loss for the nine months ended ... with a net loss of $7.1 million for the same period in 2007. The decrease in the net loss was ...

Napo Announces Positive Clinical Data Indicating Crofelemer, Could Effectively Treat Cholera

... (p=0.028, Mann-Whitney test) in the first 6 hour period (0-6 hours). A 31% reduction in normalized stool ... output was also observed during the first 12 hour period (0-12 hours) with crofelemer 125 mg every 6 hours ... a trend towards significance in the first 12 hour period (0-12 hours, p=0.155, Mann-Whitney test). ...

MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes

... received insulin aspart. Over the 52-week period of this study, A1C levels decreased comparably in ... 7.2%, comparator group). Over the 52-week period of the study, fasting blood glucose (FBG) levels ... from 180.3 mg/dL to 160.1 mg/dL over the same period in the comparator group. Patients in the TI ...

Amicus Therapeutics Announces Second Quarter 2008 Financial Results

... million as compared to $9.7 million for the same period in 2007. On a non-GAAP basis, the net loss for ... million as compared to $8.3 million in the same period in 2007. Amicus recorded revenue during the ... period from ...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

... financial results for the quarter and six month period ended June 30, 2008 and provided an update on the ... The net loss for the quarter and six month period ended June 30, 2008, as reported in accordance ... and $39.7 million in the quarter and six month period ended June 30, 2008, compared to $14.2 ...

Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration

... agreement with Trubion to extend the research period for an additional one-year period through Dec. 22, 2009. Under the terms of the research period extension, Wyeth's obligations to Trubion ...

New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes

... response to insulin glargine over a 24-hour period in patients with type 2 diabetes. "Our study ... to glargine in a single daily dose over a 24-hour period using continual glucose monitoring system (CGMS), ... glucose targets during a pre-specified basal period (12 p.m. to 6 a.m.). No food was eaten between ...

CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date

... women for up to 9.5 years, the longest follow-up period for any cervical cancer vaccine." This trial ... than 700 women aged 15-25 years. During the same period that the candidate vaccine induced sustained high ... for 776 women from the same cohort of women for a period of up to 6.4 years post-vaccination. The trial ...

Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference

... over the entire five to seven day treatment period had a rate of symptomatic intracranial hemorrhage ... Since Viprinex acts in the blood for a longer period of time than existing therapies for treatment of ... is specifically designed to double the time period that patients can be treated after the onset of a ...

Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session

... Administration (FDA) within the six month time period permissible for a priority review. Alpharma ... oral morphine sulfate. After an initial washout period from previous medications until a pain flare ... periods, each followed by a seven-day open label period on extended morphine sulfate, all at the dose ...

AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines

... study that comprised four phases: an enrollment period of up to 28 days, an open-label run-in treatment ... weeks, an open-label stabilization treatment period of 12 to 18 weeks, and a randomized-withdrawal treatment period of up to 52 weeks. The SEROQUEL XR dose was ...

Exelixis Announces First Quarter 2008 Financial Results

... to $28.1 million for the comparable period in 2007. Revenues for 2008 were generally ... compared to $50.2 million for the comparable period in 2007. The increase from 2007 to 2008 primarily ... million, or $0.25 per share, for the comparable period in 2007. The increase in net loss from 2007 to ...

Neurocrine Biosciences Reports First Quarter 2008 Results

... million, or $(0.68) per share, for the same period in 2007. Revenues for the first quarter of 2008 ... million compared with $0.1 million for the same period last year. The increase in revenues is primarily ... of 2008 compared with $19.1 million for the same period in 2007. The decrease in research and development ...

Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine

... the regulatory environment during the development period of any of our product candidates; our inability ... in, among other things, an extension in the period over which we recognize deferred revenue or our ... and in our Annual Report on Form 10-K for the period ended December 31, 2007. We do not intend to ...

U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older

... more than one of the JIA core set variables. In period A of the study, ORENCIA demonstrated consistent ... achieved an ACR Pedi 90 response rate. In period B of the study, patients who completed period A and achieved an ACR Pedi 30 response were ...

Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results

... per basic and diluted share, for the same period in 2006. Results for the fourth quarters of 2007 ... usage during the last three weeks of the dosing period compared to those receiving placebo. Achievement of abstinence for an extended period during treatment is the critical first step for ...

New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ

... a four-week, multicenter, double-blind treatment period during which 433 children were randomized to ... 4 weeks, and Visit 8 when the 6-month open label period completed. The treatment-emergent adverse event ... 0.225 cm; n=216). After the 6-month open label period (Visit 8), the adjusted mean increase in height ...

GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results

... 2007, as compared to $157,276 for the comparable period in 2006. For the full year of 2007, the Company ... of the U.S. Government. The grant funding period is over a five year period commencing October 2007. Only meritorious ...

Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

... $14.7 million, or $0.23 per share, for the same period in 2006. For the year ended December 31, 2007, ... compared to revenue of $2.6 million for the same period in 2006. For the year ended December 31, 2007, ... million compared to $10.5 million for the same period in 2006. The change included a decrease of $3.0 ...

Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache

... to placebo during the 4-hour post-treatment time period that the patients remained in the clinic. ... to placebo during the 4-hour post-treatment time period that the patients remained in the clinic. A ... remains pain-free for the remainder of the study period (up to 24 hours). The 2.5 mg dose of AZ-104 ...

Pharmasset Reports First Fiscal Quarter 2008 Financial Results

... million, or $0.33 per diluted share for the same period in fiscal 2007. Revenues were $0.5 million ... as deferred revenue. Revenues for the same period in fiscal 2007 were $8.1 million, which included ... of 2008 compared to $0.4 million during the same period in 2007. The $0.5 million increase in the first ...

CEL-SCI Corporation Reports First Quarter Financial Results

... December 31, 2006. -- During the three-month period ended December 31, 2007, research and development expenses doubled compared to the three-month period ended December 31, 2006. This is due to the ... to any other cancer therapy because that is the period when the anti-tumor immune response can still be ...

Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results

... of $8.9 million, or $0.26 per share, for the same period in 2006. As of December 31, 2007, the company had ... million, compared to $2.2 million for the same period in 2006. Fourth quarter 2007 revenues ... compared to $10.1 million for the same period in 2006 which included the one-time costs of ...

Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results

... million or $0.39 loss per share for the same period last year. For the year ended December 31, 2007, ... million compared with $9.4 million for the same period last year. The Company recognized $0.5 million in ... 2007 compared with $7.1 million for the same period in 2006, a direct result of $2.0 million in ...

Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data

... last patient will complete the active treatment period in mid-December 2007 and the two month off-treatment period in mid-February 2008. ABOUT THE SULONEX(TM) ... for 120 days were required to go into a run-in period prior to randomization of up to 120 days. This ...

Kronos Announces First Quarter Business Update and Financial Results

... $25,000 compared to $19,000 for the comparable period of 2006. Revenues for the quarter ended September ... 2007 increased $301,000 from the corresponding period of 2006 to $1,054,000. The increase was ... compared to $99,000 for the corresponding period of the prior year. The increase in interest ...

GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update

... 30, 2007, compared to $283,434 for the same period in 2006. For the nine months ended September 30, ... of the U.S. Government. The grant funding period is over a five year period commencing October 2007. Only meritorious ...

Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs

... of research and development revenues for the same period in 2006). Cost of products sold for the three-month period ended September 30, 2007 was $1.1 million as compared to $1.2 million for the same period in 2006. Included in the cost of products sold ...